Expanded Access for Vepugratinib in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Eli Lilly and Company0 个研究点开始时间: 2026年6月30日最近更新: 2026年6月30日

适应症

试验速览

阶段: 不适用
状态: Available
发起方: Eli Lilly and Company

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Have metastatic urothelial carcinoma (UC) or other solid tumor with a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration.
•Have exhausted other approved treatments, including erdafitinib for UC.
•Are not eligible for an ongoing vepugratinib clinical trial

排除标准

•Currently enrolled in an ongoing clinical study of vepugratinib
•Have a known severe (greater than or equal to (≥) Grade 3) hypersensitivity to any component or excipient of vepugratinib.
•Current evidence of corneal keratopathy or retinal disorder confirmed by ocular examination. Exception: Individuals with asymptomatic ophthalmic conditions assessed by the investigator to pose minimal risk.
•Significant cardiovascular disease:
•Are pregnant, breastfeeding, or intent to become pregnant during the study or within 6 months of the last dose of study intervention.

研究者

发起方

Eli Lilly and Company

申办方类型

Industry

责任方

Sponsor

相似试验

招募中

3 期

A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 )Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm Metastasis

2025-522855-25-00Eli Lilly & Co.197

Temporarily Not Available

不适用

Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous TreatmentsCML, RelapsedCML, Refractory

NCT07517315Sun Pharma Advanced Research Company Limited

招募中

2 期

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or RearrangementFGFR2 Gene Fusion/RearrangementOther Solid Tumors, Adult

NCT07359820Elevar Therapeutics30

尚未招募

2 期

Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)

NCT07495579Asan Medical Center146

已完成

不适用

comparing the efficacy and safety of a new Vitamin B 12 Nasal Spray vs Oral Supplement in treating Vitamin B 12 Deficiency

CTRI/2024/10/075367Dr Sabah Siddiqui50